Table 2.
Results of the scenario and sensitivity analyses
| ID | Scenario | Usual care | CardioMEMS | ICER | ||||
|---|---|---|---|---|---|---|---|---|
| LYs | QALYs | Costs | LYs | QALYs | Costs | |||
| 1 | Base case analyses (inputs from Table 1 ) | 4.79 | 2.62 | £22 770 | 4.79 | 2.94 | £29 107 | £19 671/QALY |
| 2 | £2518 for cost of HF hospitalization (assumption) | 4.79 | 2.62 | £14 870 | 4.79 | 2.94 | £23 735 | £27 519/QALY |
| 3 | £5188 for cost of HF hospitalization (assumption) | 4.79 | 2.62 | £28 262 | 4.79 | 2.94 | £32 842 | £14 217/QALY |
| 4 | Baseline HF hospitalization rate of 5.6% (using data from the CHAMPION trial) | 4.79 | 2.62 | £15 455 | 4.79 | 2.94 | £24 085 | £26 900/QALY |
| 5 | Baseline HF hospitalization rate of 11.8% (using data from COAST and MEMS‐HF) | 4.79 | 2.62 | £30 085 | 4.79 | 2.94 | £34 186 | £12 679/QALY |
| 6 | HR for HF hospitalization of 0.8 (assumption) | 4.79 | 2.62 | £22 770 | 4.79 | 2.94 | £31 719 | £27 910/QALY |
| 7 | HR for HF hospitalization of 0.178 (using data from the COAST study) | 4.79 | 2.62 | £22 770 | 4.79 | 2.95 | £18 940 | Dominant |
| 8 | HR for HF hospitalization of 0.38 (using data from the MEMS‐HF study) | 4.79 | 2.62 | £22 770 | 4.79 | 2.94 | £23 169 | £1226/QALY |
| 9 | HR for mortality of 0.8 (using data from the CHAMPION trial) | 4.79 | 2.62 | £22 770 | 5.17 | 3.17 | £30 544 | £14 234/QALY |
| 10 | HR for mortality of 1.81 (using data from subgroup analyses of the GUIDE‐HF trial) | 4.79 | 2.62 | £22 770 | 3.59 | 2.23 | £24 558 | Dominated |
HF, heart failure; HR, hazard ratio; ICER, incremental cost‐effectiveness ratio; LYs, life years; QALYs, quality‐adjusted life years.